Skip to content
All Sections
Subscribe Now
58°F
Monday, December 23rd 2024
Today's E-Edition
Home Page
Close Menu
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
SUBSCRIBE NOW
Close Menu
Sign up for email newsletters
Sign Up
Subscribe
Account Settings
Contact Us
Log Out
Spoof a user
Sign up for email newsletters
Sign Up
Subscribe
Search
Silicon Valley
58°F
Monday, December 23rd 2024
Today's E-Edition
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals, Inc. - Common Stock
(NQ:
APLS
)
33.21
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
6
Open
33.21
Bid (Size)
32.03 (1)
Ask (Size)
33.91 (1)
Prev. Close
33.21
Today's Range
33.21 - 33.21
52wk Range
24.34 - 73.80
Shares Outstanding
116,457,008
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Mama's Creations Posts Weak Earnings, Joins EVgo, Red Cat Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
December 17, 2024
Via
Benzinga
This Match Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
December 17, 2024
Via
Benzinga
Performance
YTD
-45.80%
-45.80%
1 Month
+7.93%
+7.93%
3 Month
+1.50%
+1.50%
6 Month
-13.56%
-13.56%
1 Year
-44.74%
-44.74%
More News
Read More
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (20 Ratings)
December 17, 2024
Via
Benzinga
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
A Glimpse Into The Expert Outlook On Apellis Pharmaceuticals Through 20 Analysts
November 21, 2024
Via
Benzinga
A Glimpse of Apellis Pharmaceuticals's Earnings Potential
November 04, 2024
Via
Benzinga
The Latest Analyst Ratings For Apellis Pharmaceuticals
November 04, 2024
Via
Benzinga
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 27, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Energizer, C3.ai, Insmed And Other Big Stocks Moving Higher On Tuesday
November 19, 2024
Via
Benzinga
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
November 12, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday
November 06, 2024
Via
Benzinga
Navigating 18 Analyst Ratings For Apellis Pharmaceuticals
October 16, 2024
Via
Benzinga
Why Apellis Pharmaceuticals Stock Was Tumbling on Tuesday
November 05, 2024
Via
The Motley Fool
Apellis Pharmaceuticals Dives On Worse-Than-Expected Syfovre Sales
November 05, 2024
Via
Investor's Business Daily
Celanese Posts Downbeat Results, Joins Cirrus Logic, Teradata And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
November 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 05, 2024
Via
Benzinga
Apellis Pharmaceuticals Reports Third Quarter 2024 Financial Results
November 05, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
1 Nasdaq Stock Down 62% This Year That Could Double Your Money, According to a Wall Street Analyst
October 29, 2024
Via
The Motley Fool
Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN
October 26, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on November 5, 2024, to Discuss Third Quarter 2024 Financial Results
October 22, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
October 16, 2024
Via
Benzinga
Apellis Announces Oral Presentation at American Society of Nephrology (ASN) Kidney Week on Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
October 16, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
September 25, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
September 23, 2024
Via
Benzinga
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close